<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Niagen Bioscience, Inc. — News on 6ix</title>
<link>https://6ix.com/company/niagen-bioscience-inc</link>
<description>Latest news and press releases for Niagen Bioscience, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:32:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/niagen-bioscience-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a05478dffbe2df108d77.webp</url>
<title>Niagen Bioscience, Inc.</title>
<link>https://6ix.com/company/niagen-bioscience-inc</link>
</image>
<item>
<title>Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-report-first-quarter-2026-financial-results-on-wednesday-may-6-2026</guid>
<pubDate>Wed, 22 Apr 2026 12:32:00 GMT</pubDate>
<description>LOS ANGELES, April 22, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026.</description>
</item>
<item>
<title>Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-collaborates-with-usp-to-establish-first-ever-usp-monograph-for-nicotinamide-riboside-chloride-nrcl-the-patented-form-in-niagenr</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-collaborates-with-usp-to-establish-first-ever-usp-monograph-for-nicotinamide-riboside-chloride-nrcl-the-patented-form-in-niagenr</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and</description>
</item>
<item>
<title>Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-first-cruise-ship-clinic-partnership-with-onespaworld-bringing-the-nad-boosting-benefits-of-niagen-iv-to-the-high-seas</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-first-cruise-ship-clinic-partnership-with-onespaworld-bringing-the-nad-boosting-benefits-of-niagen-iv-to-the-high-seas</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc.</description>
</item>
<item>
<title>Niagen Bioscience Increases Share Repurchase Program to $20 Million</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-increases-share-repurchase-program-to-dollar20-million</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-increases-share-repurchase-program-to-dollar20-million</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the</description>
</item>
<item>
<title>Niagen Bioscience to Present at the 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-present-at-the-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-present-at-the-38th-annual-roth-conference</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the</description>
</item>
<item>
<title>Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-surpasses-300-external-research-agreements-from-leading-global-institutions-on-niagenr-contributing-to-45-published-clinical-studies</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-surpasses-300-external-research-agreements-from-leading-global-institutions-on-niagenr-contributing-to-45-published-clinical-studies</guid>
<pubDate>Tue, 17 Mar 2026 12:32:00 GMT</pubDate>
<description>LOS ANGELES, March 17, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world.</description>
</item>
<item>
<title>Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-launches-niagenr-skincare-innovation-lab-and-debuts-dermatologist-tested-niagen-nanocloudtm-from-tru-niagen-powered-by-patented-niagenr-17</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-launches-niagenr-skincare-innovation-lab-and-debuts-dermatologist-tested-niagen-nanocloudtm-from-tru-niagen-powered-by-patented-niagenr-17</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Launch expands Niagen® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation</description>
</item>
<item>
<title>Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-reports-30percent-year-over-year-net-sales-increase-to-dollar1294-million-103percent-net-income-increase-to-dollar174-million-or-dollar022-basic-eps-in-2025-79</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-reports-30percent-year-over-year-net-sales-increase-to-dollar1294-million-103percent-net-income-increase-to-dollar174-million-or-dollar022-basic-eps-in-2025-79</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103%</description>
</item>
<item>
<title>Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-streamline-and-focus-its-operations-with-the-sale-of-chromadex-reference-standards-business-to-lgc-in-all-cash-transaction</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-to-streamline-and-focus-its-operations-with-the-sale-of-chromadex-reference-standards-business-to-lgc-in-all-cash-transaction</guid>
<pubDate>Thu, 26 Feb 2026 12:02:00 GMT</pubDate>
<description>LOS ANGELES, February 26, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience’s operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual prop</description>
</item>
<item>
<title>Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-secures-new-us-patent-covering-intravenous-and-injection-formulations-and-methods-of-use-for-nicotinamide-riboside-nr-niagenr</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-secures-new-us-patent-covering-intravenous-and-injection-formulations-and-methods-of-use-for-nicotinamide-riboside-nr-niagenr</guid>
<pubDate>Wed, 25 Feb 2026 13:32:00 GMT</pubDate>
<description>LOS ANGELES, February 25, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations.</description>
</item>
<item>
<title>Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of Copenhagen</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-premiere-sponsor-inaugural-133400543</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-premiere-sponsor-inaugural-133400543</guid>
<pubDate>Mon, 09 Feb 2026 13:34:00 GMT</pubDate>
<description>LOS ANGELES, February 09, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required;</description>
</item>
<item>
<title>Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-premiere-sponsor-inaugural-nad-health-opportunities-challenges</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-premiere-sponsor-inaugural-nad-health-opportunities-challenges</guid>
<pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
<description>Taking place March 23-25, 2026, this three-day scientific forum will convene the world’s foremost NAD experts in Copenhagen to advance evidence-based</description>
</item>
<item>
<title>Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-report-fourth-quarter-133200705</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-report-fourth-quarter-133200705</guid>
<pubDate>Fri, 06 Feb 2026 13:32:00 GMT</pubDate>
<description>LOS ANGELES, February 06, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on We</description>
</item>
<item>
<title>Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-expands-hsa-fsa-133400779</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-expands-hsa-fsa-133400779</guid>
<pubDate>Thu, 15 Jan 2026 13:34:00 GMT</pubDate>
<description>LOS ANGELES, January 15, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it has partnered with Truemed to provide qualified customers the option to purchase Tru Niagen®, the number one NAD+ supplement in the United States*, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds on its direct-to-consumer website, www.truniagen.com. Qualified custo</description>
</item>
<item>
<title>Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-acquires-existing-core-nicotinamide-riboside-nr-patent-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-acquires-existing-core-nicotinamide-riboside-nr-patent-portfolio</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+</description>
</item>
<item>
<title>Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-launches-tru-niagenr-beauty-first-nad-skincare-supplement-us</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-launches-tru-niagenr-beauty-first-nad-skincare-supplement-us</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>This science-backed blend of Niagen and clinically studied actives is designed to support healthy skin, hair, and nails LOS ANGELES--(BUSINESS WIRE)-- Niagen</description>
</item>
<item>
<title>Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-results-first-ever-randomized-controlled-trial-exploring</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-results-first-ever-randomized-controlled-trial-exploring</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Findings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality LOS ANGELES--(BUSINESS WIRE)-- Niagen</description>
</item>
<item>
<title>Niagen Bioscience Announces $10 Million Share Repurchase Program</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-10-million-share-repurchase-program-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-announces-10-million-share-repurchase-program-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the</description>
</item>
<item>
<title>Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-inc-reports-third-quarter-2025-financial-results-and-reaffirms</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-inc-reports-third-quarter-2025-financial-results-and-reaffirms</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior year Adjusted</description>
</item>
<item>
<title>Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025</title>
<link>https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-report-third-quarter-2025-financial-results-tuesday-november-4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/niagen-bioscience-inc/news/niagen-bioscience-report-third-quarter-2025-financial-results-tuesday-november-4-2025</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the</description>
</item>
</channel>
</rss>